Discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell

Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field. 

Year Invested: 2013
Location: San Francisco, Calif.

Recent News

April 4, 2019
Nurix Therapeutics to Present at the Needham & Company 18th Annual Healthcare Conference

March 19, 2019
Nurix Therapeutics to Present at 2019 American Association for Cancer Research (AACR) Annual Meeting

November 7, 2018
Nurix Therapeutics to Present at the Stifel Healthcare Conference

Read More News

Associated Team Members

Jeffrey Tong, Ph.D.